Skip to main content

Home/ Health Now/ Group items tagged “oral

Rss Feed Group items tagged

Matti Narkia

Maté: a risk factor for oral and oropharyngeal cancer - Oral Oncol. 2002 Oct;... - 0 views

  •  
    Maté: a risk factor for oral and oropharyngeal cancer. Goldenberg D. Oral Oncol. 2002 Oct;38(7):646-9. Review. PMID: 12167417
tan choonpang

Oral Hygiene Care For Life | Health Tips Blog - 0 views

  •  
    Making a habit of practicing good oral hygiene care can really pay off but in more ways than you might first think. You can prevent most common diseases
Matti Narkia

Safety evaluation of topical applications of ethanol on the skin and inside the oral ca... - 0 views

  •  
    Safety evaluation of topical applications of ethanol on the skin and inside the oral cavity. Lachenmeier DW. J Occup Med Toxicol. 2008 Nov 13;3:26. PMID: 19014531 doi:10.1186/1745-6673-3-26
Matti Narkia

An estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of o... - 0 views

  •  
    Grant WB, Garland CF, Gorham ED. \nAn estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of oral vitamin D per day.\nRecent Results Cancer Res. 2007;174:225-34.\nPMID: 17302200 [PubMed - in process]
Matti Narkia

Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalcif... - 0 views

  •  
    Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol.Am J Clin Nutr. 2003 Jan;77(1):204-10. Erratum in: Am J Clin Nut
Matti Narkia

Oral administration of active hexose correlated compound enhances host resistance to We... - 0 views

  •  
    Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. Wang S, Welte T, Fang H, Chang GJ, Born WK, O'Brien RL, Sun B, Fujii H, Kosuna K, Wang T. J Nutr. 2009 Mar;139(3):598-602. Epub 2009 Jan 13. PMID: 19141700 doi:10.3945/jn.108.100297
Matti Narkia

Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency: A Meta-an... - 0 views

  •  
    Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J. Arch Intern Med. 2009 Mar 23;169(6):551-61. PMID: 19307517 Conclusion Nonvertebral fracture prevention with vitamin D is dose dependent, and a higher dose should reduce fractures by at least 20% for individuals aged 65 years or older.
Matti Narkia

One dose of vitamin D boosts TB immunity - New Zealand's source for health news on Stuf... - 0 views

  •  
    In healthy people who have been exposed to tuberculosis, a single oral dose of vitamin D enhances their immunity against this bacterial infection.
Matti Narkia

Beta Glucan Research - 0 views

  •  
    Beta glucan is a scientifically proven biological defense modifier (BDM) that nutritionally potentiates and modulates the immune response. As a supplement, after swallowing orally, Beta glucan is ingested primarily through macrophage and dendritic immune cells, to nutritionally and safely yield, through immune response potentiation and modulation, in many instances various therapeutic healing effects generated by the immune cells.  For many years Glucans have been investigated (History) for these immune enhancing properties, particularly their ability to activate macrophage immune cells and NK-Cells, plus in turn, the T-Cells, and B-Cells including selected cytokines and complement. 
Matti Narkia

Sloan-Kettering - Garlic - 0 views

  •  
    Derived from the bulb or clove of the plant. Garlic is used as a spice and to treat hyperlipidemia, hypertension, atherosclerosis, cancer, and infections. Processing can have a substantial effect on the chemical content in garlic; the volatile oil components are sensitive to heat and certain enzymes are acid-labile. Several oral garlic formulations are available, and clinical studies have addressed a variety of the proposed claims. Placebo-controlled trials on the cholesterol lowering effect of garlic yielded mixed results (16) (17) (18) (21) (22) (26). Studies evaluating the antithrombotic effects repeatedly have shown modest reduction in platelet aggregation, but varying levels of fibrinolytic activity. Research shows mixed effects with regard to reductions in blood glucose, blood pressure, or risk of cardiovascular disease (23). Frequently reported adverse events include bad breath, headache, fatigue, GI upset, diarrhea, sweating, and possible hypoglycemia (9). Because garlic is known to decrease platelet aggregation and potentially elevate the INR, it should not be used with anticoagulants or in patients with platelet dysfunction (15). Garlic appears to induce cytochrome p450 3A4 and may enhance metabolism of many medications (e.g. cyclosporin and saquinavir) (12). An analysis of several case-control studies in Europe suggests an inverse association between garlic consumption and risk of common cancers (25).
Matti Narkia

Omega-3 Fatty Acids May Benefit Cancer Patients Undergoing Major Operations - 0 views

  •  
    ScienceDaily (Apr. 10, 2009) - New research from Trinity College Dublin published in this month's Annals of Surgery points to a potentially significant advance in the treatment of patients undergoing major cancer surgery. The study was carried out by the oesophageal research group at Trinity College Dublin and St James's Hospital. A randomised controlled trial showed omega-3 fatty acids given as part of an oral nutritional supplement resulted in the preservation of muscle mass in patients undergoing surgery for oesopahageal cancer, a procedure normally associated with significant weight loss and quality of life issues.
Matti Narkia

The beverage maté: a risk factor for cancer of the head and neck. - Head Neck... - 0 views

  •  
    The beverage maté: a risk factor for cancer of the head and neck. Goldenberg D, Golz A, Joachims HZ. Head Neck. 2003 Jul;25(7):595-601. Review. PMID: 12808663 DOI: 10.1002/hed.10288
Dr. John Bureau DC

Medical News: AAN: Epilepsy Drug Not Effective for Chronic Headache - in Meeting Covera... - 0 views

  • SEATTLE, April 30 -- The epilepsy drug levetiracetam (Keppra) does not appear to be effective for prevention of chronic daily headache, researchers said here. Action Points  Explain that the epilepsy drug levetiracetam did not significantly increase the headache-free rate for patients with chronic daily headache compared with placebo.Note, however, that there was a significant reduction in disability and reduced pain severity in the treatment group, and the findings show that there is a subpopulation of chronic daily headache patients for whom levetiracetam remains a therapeutic option.Note that this study was published as an abstract and presented orally at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal. Levetiracetam drug achieved a 3.9% increase in headache-free performance over placebo, but the trend did not reach statistical significance, Roy Beran, M.D., of the University of New South Wales, and colleagues reported at the American Academy of Neurology meeting.
  •  
    SEATTLE, April 30 -- The epilepsy drug levetiracetam (Keppra) does not appear to be effective for prevention of chronic daily headache, researchers said here. Levetiracetam drug achieved a 3.9% increase in headache-free performance over placebo, but the trend did not reach statistical significance, Roy Beran, M.D., of the University of New South Wales, and colleagues reported at the American Academy of Neurology meeting.
1 - 17 of 17
Showing 20 items per page